Our M-gager® Platform

Our M-gager® Platform

IMMUNOTHERAPIES

The advent of immunotherapies have ushered in a new era in cancer treatment, offering new hope beyond traditional methods. However, while promising, to date they have only shown efficacy in certain patient populations and suffer from a high degree of off-tumor activity due to lack of tumor selectivity. This severely compromises the efficacy and safety of these promising therapies. Targeting antigens restricted to tumor cells is essential for the design and delivery of novel, truly impactful immunotherapies. CDR-Life is at the forefront of developing next-generation T cell engagers with enhanced tumor selectivity. Our goal is to enhance therapeutic efficacy while reducing side effects, potentially expanding the reach of these innovative therapies to benefit a wider range of patients.

Our M-gager® Platform

Tumor-Targeted T cell engager

Based on more than 20 years of experience in cutting-edge antibody fragment design, engineering, and production, CDR-Life’s integrated end-to-end antibody-based platform facilitates the development of novel tumor-targeted T cell engagers (TCEs), addressing hard-to-treat solid tumors through enhanced tumor selectivity. We are harnessing our platform to advance a pipeline of potent, tumor-selective TCEs that target both intracellular and surface tumor antigens.

M-gager®, CDR-Life’s unique antibody platform, delivers a modular technology with unparalleled tumor antigen specificity, allowing selective targeting of tumor cells while sparing healthy tissues.

pMHC targeting: This approach targets antigens present inside tumor cells that are displayed on the major histocompatibility complex (MHC), ensuring high tumor specificity.

2+1 format: This format enhances selectivity through avidity, capitalizing on expression differences between tumor and normal tissues.

Tri-specificity: This approach aims to selectively tumor cells that co-express two target antigens, sparing normal cells that express only one of these targets.

M-gager® enables the development of truly tumor-specific and -eradicating T cell engagers, overcoming the limitations of non-tumor selectivity that currently prevent existing treatments from achieving their full therapeutic potential.

M-gager® properties

CDR-Life’s M-gager® platform is our proprietary technology designed to develop highly tumor-targeted, antibody-derived T cell engagers. Utilizing a unique phage display library with billions of small antibody fragments, we deliver a modular technology that achieves unparalleled tumor antigen specificity in the T cell engager format, leading to effective and tumor-selective T cell recruitment. M-gager® molecules have excellent drug properties and are anticipated to be highly effective immunotherapies for a wide range of promising targets.

How do M-gager® molecules work?


The unique tumor antigen-specific moieties recognize and attach to cancer cells, while the anti-CD3 effector function engages CD3 on T cells. Concurrently, they signal a patient’s T cells to create a powerful cancer-fighting zone. The simultaneous binding of both the tumor antigen and CD3 promotes the formation of a cytolytic synapse between T cells and tumor cells, enabling T cells to release special proteins that can break down cancer cells without harming healthy ones.
As this process happens, the patient’s body creates more T cells specifically trained to recognize these cancer cells. Some of these new T cells become ‘memory cells,’ providing ongoing protection against cancer’s return. This immunological memory forms the basis for durable responses observed in some patients following successful immunotherapy. The activated T cells send out signals to attract even more immune cells to the tumor site. The result? A coordinated, multi-pronged attack on cancer cells that can lead to more effective and longer-lasting treatment outcomes.

Collectively, M-gager® molecules trigger a cascade of T cell biological effects including (1) T cell activation, (2) polyclonal expansion, (3) memory formation, and (4) peripheral recruitment, which together facilitate the synergistic lysis of tumor cells.